Table 1.
Clinical characteristics of patients with NK/T-LAHS.
| Characteristics | No. (n = 21, %) |
|---|---|
| Gender | |
| Male | 17/21(81.0) |
| Female | 4/21(19.0) |
| Age(years), median(range) | 35(16–65) |
| Ann Arbor stage | |
| I – II | 5/21(23.8) |
| III – IV | 16/21(76.2) |
| ECOG PS | |
| 0–1 | 9/21(42.9) |
| 2–4 | 12/21(57.1) |
| Fever | 21/21(100.0) |
| Hepatosplenomegaly | 14/21(66.7) |
| Lymphadenopathy | 13/21(61.9) |
| BM involvement | 8/21(38.1) |
| Lymphoma status | |
| At onset | 19/21(90.5) |
| At relapse | 2/21(9.5) |
| Triglyceride>3mmol/L | 12/21(57.1) |
| Fibrinogen<1.5 g/L | 16/21(76.2) |
| Ferritin>2000 ng/mL | 21/21(100) |
| Hemocytopenia involving at least 2 lineages | 21/21(100) |
| Hemophagocytosis in bone marrow | 10/21(47.6) |
| LDH>ULN | 18/21(85.7) |
| Liver dysfunction | 21/21(100) |
ECOG PS the Eastern Cooperative Oncology Group performance status, BM bone marrow, LDH lactate dehydrogenase, ULN upper limit of normal. The criteria for liver dysfunction is jaundice, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >ULN. Hepatits and drug related damage are not included.